| Detected | Trial | Change |
|---|---|---|
| 2026-08-02 | NCT04651348 A Clinical Study of MIL95 in Advanced Malignancies. |
overall status: Recruiting → Unknown |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 3 | |||
| NCT04834024 | MIL62 Combined With Lenalidomide Versus Lenalidomide for Patients With Rituximab… | Follicular Lymphoma and Marginal Zone Lymphoma | Recruiting |
| NCT07405970 | A Phase 3 Clinical Study of MIL62 in Systemic Lupus Erythematosus | Systemic Lupus Erythematosus | Recruiting |
| NCT05862233 | A Phase Ⅲ Clinical Study of MIL62 in Primary Membranous Nephropathy | Primary Membranous Nephropathy | Active, Not Recruiting |
| NCT05314010 | A Study of MIL62 in Patients With Neuromyelitis Optica Spectrum Disorder (NMOSD) | Neuromyelitis Optica Spectrum Disorder | Active, Not Recruiting |
| Phase 2 | |||
| NCT05796206 | A Phase 2 Clinical Study of MIL62 in Systemic Lupus Erythematosus | Systemic Lupus Erythematosus | Active, Not Recruiting |
| Phase 1/2 | |||
| NCT06232096 | A Study of MBS314 in Participants With Relapsed/Refractory Multiple Myeloma. | Relapsed or Refractory Multiple Myeloma | Recruiting |
| NCT04110301 | MIL62 Plus Lenalidomide for Patients With Relapsed/Refractory Indolent Non-Hodgkin's… | Follicular Lymphoma and Marginal Zone Lymphoma | Recruiting |
| NCT05806099 | A Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy Study of MBS303… | Non-Hodgkin's Lymphoma | Recruiting |
| NCT07375758 | A Study of MIL116 in Healthy Participants and Patients With IgA Nephropathy. | Immunoglobulin A Nephropathy | Recruiting |
| NCT07044115 | Evaluation of the Tolerance, Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of… | Lupus Nephritis | Active, Not Recruiting |
| Phase 1 | |||
| NCT04965077 | Treatment of Advanced and Metastatic Solid Tumors With MIL97 | Advanced or Metastatic Solid Tumor | Recruiting |
| NCT03842085 | Phase I Clinical Study of MBS301 in Treatment of HER2 Positive Recurrent or Metastatic… | HER2-positive Recurrent or Metastatic Malignant Solid Tumor | Recruiting |